By a News Reporter-Staff News Editor at Drug Week -- Fresh data on Oncology are presented in a new report. According to news reporting from Qingdao, People's Republic of China, by NewsRx journalists, research stated, "Development of functional biomaterials and drugs with good biocompatibility towards host cells but with high potency against cancer cells is a challenging endeavor. By drawing upon the advantageous features of natural antimicrobial peptides and ?-helical proteins, we have designed a new class of short ?-helical peptides G(IIKK)(n)I-NH2 (n=1-4) with different potency and high selectivity against cancer cells."
The news correspondents obtained a quote from the research from the East China University of Petroleum, "We show that the peptides with n=3 and 4 kill cancer cells effectively whilst remaining benign to the host cells at their working concentrations, through mechanistic processes similar to their bactericidal effects. The high cell selectivity could stem from their preferential binding to the outer cell membranes containing negative charges and high fluidity. In addition to rapid membrane-permeabilizing capacities, the peptides can also induce the programmed cell death of cancer cells via both mitochondrial pathway and death receptor pathway, without inducing non-specific immunogenic responses. Importantly, these peptides can also inhibit tumor growth in a mouse xenograft model without eliciting side effects."
According to the news reporters, the research concluded: "Whilst this study reveals the clinical potential of these peptides as potent drugs and for other medical and healthcare applications, it also points to the significance of fundamental material research in the future development of highly selective peptide functional materials."
For more information on this research see: Molecular mechanisms of anticancer action and cell selectivity of short ?-helical peptides. Biomaterials, 2014;35(5):1552-61. (Elsevier - www.elsevier.com; Biomaterials - www.elsevier.com/wps/product/cws_home/30392)
Our news journalists report that additional information may be obtained by contacting C. Chen, Centre for Bioengineering and Biotechnology, China University of Petroleum (East China), 66 Changjiang West Road, Qingdao 266580, People's Taiwan. Additional authors for this research include J. Hu, P. Zeng, F. Pan, M. Yaseen, H. Xu and J.R Lu (see also Oncology).
Keywords for this news article include: Asia, Cancer, Qingdao, Therapy, Oncology, Peptides, Proteins, Proteomics, Amino Acids, People's Republic of China.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC